CEO David King said that the acquisition of Sequenom positions LabCorp as a leader in NIPT, women's health, and reproductive genetics.
The court ordered the molecular diagnostic company to stop offering the Fetalis test it started offering in Germany this summer, which is based on Ariosa's technology.
Multiple variant databases are creating competition among groups that disagree on how to advance the most scientifically robust and sustainable sharing model.
Experts said that the EMR is a crucial channel for aggregating clinical insights from multiple sources, but plenty of work is needed to achieve broader adoption.
Experts at CAP16 said most practicing pathologists operate within specialties and rarely cross the divide into other test disciplines, which thwarts optimal patient care.
ClearPath offers laboratory diagnostic services in the northeastern US, including Hologic assays, PCR testing, and the Illumigene HSV 1&2 test.
The $302 million deal, which was expected to close by the end of the year, passed US government antitrust review in August.
The deal is still subject to other closing requirements including meeting a minimum tender condition.
Sequenom, which will be acquired by LabCorp this year, saw an increase in testing for average-risk pregnancies in the quarter, despite lower overall revenues.
A month after Brexit fears pushed the GenomeWeb Index down half a percent, companies rallied on news of an acquisition and better than expected Q2 performances.
Wired reports on how genetic genealogy's use in forensics has exploded in the year since an arrest in the Golden State Killer case was made.
Retraction Watch reports that the increase in retracted papers at a journal is due to more resources there to tackle publication ethics.
New York City has settled with a forensic scientist who was fired after questioning a DNA testing approach used by the medical examiner's office, the New York Times reports.
In Nature this week: technique for measuring replication fork movement, WINTHER trial results, and more.